WO2005021022A3 - Stable formulations of peptides - Google Patents

Stable formulations of peptides Download PDF

Info

Publication number
WO2005021022A3
WO2005021022A3 PCT/DK2004/000576 DK2004000576W WO2005021022A3 WO 2005021022 A3 WO2005021022 A3 WO 2005021022A3 DK 2004000576 W DK2004000576 W DK 2004000576W WO 2005021022 A3 WO2005021022 A3 WO 2005021022A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
stable formulations
formulations
stable
glucagon
Prior art date
Application number
PCT/DK2004/000576
Other languages
French (fr)
Other versions
WO2005021022A2 (en
Inventor
Morten Schlein
Svend Ludvigsen
Original Assignee
Novo Nordisk As
Morten Schlein
Svend Ludvigsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Morten Schlein, Svend Ludvigsen filed Critical Novo Nordisk As
Priority to JP2006525045A priority Critical patent/JP5518282B2/en
Priority to EP04762796A priority patent/EP1663295A2/en
Publication of WO2005021022A2 publication Critical patent/WO2005021022A2/en
Publication of WO2005021022A3 publication Critical patent/WO2005021022A3/en
Priority to US11/365,274 priority patent/US20060247167A1/en
Priority to US12/752,634 priority patent/US20100190715A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Method for increasing the shelf-life of a pharmaceutical formulation comprising a glucagon-like peptide.
PCT/DK2004/000576 2003-09-01 2004-08-31 Stable formulations of peptides WO2005021022A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006525045A JP5518282B2 (en) 2003-09-01 2004-08-31 Stable peptide formulation
EP04762796A EP1663295A2 (en) 2003-09-01 2004-08-31 Stable formulations of peptides
US11/365,274 US20060247167A1 (en) 2003-09-01 2006-03-01 Stable formulations of peptides
US12/752,634 US20100190715A1 (en) 2003-09-01 2010-04-01 Stable Formulations of Peptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301239 2003-09-01
DKPA200301239 2003-09-01
US50115703P 2003-09-08 2003-09-08
US60/501,157 2003-09-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/365,274 Continuation US20060247167A1 (en) 2003-09-01 2006-03-01 Stable formulations of peptides

Publications (2)

Publication Number Publication Date
WO2005021022A2 WO2005021022A2 (en) 2005-03-10
WO2005021022A3 true WO2005021022A3 (en) 2005-06-30

Family

ID=34276702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000576 WO2005021022A2 (en) 2003-09-01 2004-08-31 Stable formulations of peptides

Country Status (3)

Country Link
EP (1) EP1663295A2 (en)
JP (1) JP5518282B2 (en)
WO (1) WO2005021022A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
ATE501710T1 (en) 2005-01-14 2011-04-15 Camurus Ab SOMATOSTATIN ANALOG FORMULATIONS
ES2343641T3 (en) 2005-01-14 2010-08-05 Camurus Ab TOPIC BIOADHESIVE FORMULATIONS.
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
PL1888031T3 (en) * 2005-06-06 2013-04-30 Camurus Ab Glp-1 analogue formulations
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
NZ592283A (en) 2008-10-17 2012-09-28 Sanofi Aventis Deutschland Combination of an insulin and the GLP-1 agonist AVE0010
JP4959005B2 (en) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス Treatment of diabetes mellitus with insulin injections less than daily injection frequency
US8903364B2 (en) 2009-01-16 2014-12-02 Broadcom Corporation Method and system for processing and delivery of multimedia content by an integrated femtocell and set-top-box device
US9060098B2 (en) 2009-01-16 2015-06-16 Broadcom Corporation Method and system for data processing in a device with integrated set-top-box and femtocell functionality
US20100210239A1 (en) 2009-02-17 2010-08-19 Jeyhan Karaoguz Service mobility via a femtocell infrastructure
US9049652B2 (en) 2009-02-27 2015-06-02 Broadcom Corporation Method and system for controlling access and utilization of femtocells via a network based service
US8855048B2 (en) 2009-02-27 2014-10-07 Broadcom Corporation Method and system for peer-to-peer cellular communications
US8259617B2 (en) 2009-03-18 2012-09-04 Broadcom Corporation Method and system for timely delivery of multimedia content via a femtocell
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc Glp-1 receptor agonist compounds for sleep enhancement
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
DE102010011919A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Liquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine
MX2012005184A (en) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine.
MX2012005186A (en) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine.
JP6199186B2 (en) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
DK2632478T3 (en) 2010-10-27 2019-10-07 Novo Nordisk As TREATMENT OF DIABETES MELITUS USING INSULIN INJECTIONS SUBMITTED AT VARIOUS INJECTION INTERVALS
WO2012088157A2 (en) 2010-12-22 2012-06-28 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists for islet cell transplantation
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
KR102139080B1 (en) 2012-05-25 2020-07-29 카무러스 에이비 Somatostatin receptor agonist formulations
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
PL2934567T3 (en) 2012-12-21 2018-10-31 Sanofi Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
CN114939156A (en) 2014-01-09 2022-08-26 赛诺菲 Stabilized pharmaceutical formulations of insulin aspart
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP6970615B2 (en) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Insulin glargine / lixisenatide fixed ratio prescription
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
MX2018007859A (en) 2015-12-23 2018-11-09 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists.
JOP20190177A1 (en) 2017-01-17 2019-07-16 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
KR20200019122A (en) 2017-06-20 2020-02-21 암젠 인크 Methods of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptors (GIPR) in combination with GLP-1 agonists
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP6612004B1 (en) * 2018-07-31 2019-11-27 株式会社親広産業 Glucose consumption promoter and glycolysis promoter
WO2020026471A1 (en) * 2018-07-31 2020-02-06 株式会社親広産業 Glucose consumption promoter and glycolysis promoter
GB201917723D0 (en) * 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
EP4259646A1 (en) * 2020-12-11 2023-10-18 IP2IPO Innovations Limited Novel compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041546A2 (en) * 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
US20010014666A1 (en) * 1997-12-16 2001-08-16 Ronald Norbert Hermeling Glucagon-like peptide-1 crystals
US20010027180A1 (en) * 1999-12-30 2001-10-04 Isaacs Indu J. GLP-2 formulations
WO2002048183A2 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Compositions of peptide crystals
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2005000222A2 (en) * 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431173A1 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010014666A1 (en) * 1997-12-16 2001-08-16 Ronald Norbert Hermeling Glucagon-like peptide-1 crystals
WO2000041546A2 (en) * 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
US20010027180A1 (en) * 1999-12-30 2001-10-04 Isaacs Indu J. GLP-2 formulations
WO2002048183A2 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Compositions of peptide crystals
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2005000222A2 (en) * 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease

Also Published As

Publication number Publication date
JP2007504178A (en) 2007-03-01
WO2005021022A2 (en) 2005-03-10
EP1663295A2 (en) 2006-06-07
JP5518282B2 (en) 2014-06-11

Similar Documents

Publication Publication Date Title
WO2005021022A3 (en) Stable formulations of peptides
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
WO2006051103A3 (en) Stable formulations of peptides
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
AU2003239609A1 (en) 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
PL1633390T3 (en) Stabilized pharmaceutical glp-1 peptide compositions
MXPA03006775A (en) Pharmaceutical formulation.
IL207028A0 (en) Pharmaceutical nati-tnf-alpha antibody formulation
AU2003210243A1 (en) Method for systemic drug delivery through the nail
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
MXPA03007641A (en) Pharmaceutical formulation.
PL1633391T3 (en) Stabilized pharmaceutical peptide compositions
AU2002217373A1 (en) Controlled release pharmaceutical formulation containing venlafaxine
AU2003250372A1 (en) Pharmaceutical composition
AU2003245504A1 (en) Pharmaceutical compositions for drugs having ph-dependentsolubility
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
HUP0303948A2 (en) Solid orally-dispersible pharmaceutical formulation
AU2003238039A1 (en) Nasal peptide pharmaceutical formulation
ZA200402729B (en) Pharmaceutical formulation comprising (R) -bicalutamide.
WO2005030142A3 (en) Rifalazil formulations
AU2003215706A1 (en) Orodispersible pharmaceutical composition comprising ivabradine
AU2003215708A1 (en) Orodispersible pharmaceutical composition comprising perindopril
IL173626A0 (en) Small peptides and oral pharmaceutical compositions containing the same
AU2003216335A1 (en) Analytics delivery platform
AU2003275006A1 (en) Aerosol drug delivery system employing formulation pre-heating

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004762796

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006525045

Country of ref document: JP

Ref document number: 11365274

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004762796

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11365274

Country of ref document: US